Teva advised ANP that after performing certain steps in the...

Teva advised ANP that after performing certain steps in the development process, ATL1102 was determined to no longer be in line with Teva’s preferred product profile. ANP understands that business considerations or factors contributing to Teva’s decision include issues with one of the long-term toxicological studies that may require repeat of the study, lengthening the development time and time to market of the drug.
Wonder if the problems have been sorted yet?
Nearly a bill shares on issue would have to raise money might dilute more if no info comes out.
No debt so only spending on research hopefully and finding some partneres with big pockets.
Good luck all